학술논문
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab
Document Type
Article
Author
Schwartzberg, L.S.; Tauer, K.W.; Stepanski, E.J.; Hermann, R.C.; Keaton, M.; Makari-Judson, G.; Isaacs, C.; Beck, J.T.; Kaklamani, V.; Starr, A.; Rugo, H.S.; Wang, W.; Eisenberg, P.; Ro, S.K.; Lokker, N.A.; Bell-McGuinn, K.; Hudis, C.A.; Kirshner, J.J.; Levine, E.; Emanuelson, R.; Medgyesy, D.C.; Qamar, R.
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 15 May 2013, 19(10):2745-2754)
Subject
Language
English
ISSN
15573265
10780432
10780432